Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression

TY - JOUR

T1 - Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression

AU - Gregg, L. Parker

AU - Carmody, Thomas

AU - Le, Dustin

AU - Toto, Robert D.

AU - Trivedi, Madhukar H.

AU - Hedayati, S. Susan

N1 - Funding Information: Study concept and design: SSH, RDT, MHT; acquisition, analysis, or interpretation of data: SSH, LPG, TC, MHT, DL; statistical analysis: TC; obtained funding: SSH; study supervision: SSH. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that the questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. This work was supported by NIDDK grant R01DK085512 and a VA MERIT grant (CX000217-01) awarded to S. Hedayati. Support was also provided by the UTSW Medical Center O'Brien Kidney Research Core Center (NIDDK grant P30DK079328). This work is also conducted with support from UT-STAR, NIH/NCATS grant UL1RR024982, NIDDK grant T32DK007257 (L. Gregg), and the Center for Depression Research and Clinical Care (Hersh Foundation). The funding organizations had no role in the study design; collection, analysis, and interpretation of the data; writing the report; or the decision to submit the report for publication. RDT has received consulting fees from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Novo Nordisk, Reata, Relypsa, and ZS Pharma. MHT has served as an advisor or consultant to Allergan Sales LLC, Alkermes, Arcadia Pharmaceuticals Inc, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Eli Lilly & Co, Evotec, Johnson & Johnson, Lundbeck, MedAvante, Merck, MSI Methylation Sciences Inc, Nestle Health Science-PamLab Inc, Naurex, Neuronetics, One Carbon Therapeutics Ltd, Otsuka Pharmaceuticals, Roche Products Ltd, SHIRE Development, Takeda, and Tal Medical/Puretech Venture. The remaining authors declare that they have no other relevant financial interests. We are grateful to all the patients who participated in CAST. We thank the following individuals who were not financially compensated for their role in the study: Data and Safety Monitoring Boards at the UTSW site (Beverley Adams-Huet, MS, Sherwood Brown, MD, Kevin C. Kelly, PharmD, and Robert F. Reilly, MD) and the Central VA (Clinical Science Research and Development, Central Data Monitoring Committee, Hines CSPCC); psychiatry consultants (Benji Kurian, MD [UTSW] and Collin Vas, MBBS [Dallas VA]); nephrology faculty (Peter Van Buren, MD, MSc [UTSW]); and UTSW nephrology residents and fellows (Masoud Afshar, MD, Lei Chen, MD, Michael Concepcion, MD, Vishal Jaikaransingh, MD, Naseem Sunnoqrot, MD, Venkata Yalamanchili, MBBS). We also acknowledge the UTSW research personnel who were compensated for their role: Anuoluwapo Adelodun, MBBS, MPH, Patricia Alvarez, MSW, Mieshia Beamon, MS, Susamei Khamphong, BA, Ammar Nassri, MD, Michael Phan, PharmD, MBA, MHSM, David Rezaei, PharmD (Dallas VA site), Staci Schwartz, BA, Francisco Sanchez, BS, Kyle West, MS, and the UTSW Nephrology Clinical and Translational Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK, the National Institutes of Health, or the Department of Veterans Affairs. Parts of these results were presented in abstract form at the American Society of Nephrology Kidney Week meeting; October 25, 2018; San Diego, CA. Received December 4, 2018. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form September 10, 2019. Funding Information: This work was supported by NIDDK grant R01DK085512 and a VA MERIT grant ( CX000217-01 ) awarded to S. Hedayati. Support was also provided by the UTSW Medical Center O’Brien Kidney Research Core Center ( NIDDK grant P30DK079328 ). This work is also conducted with support from UT-STAR, NIH / NCATS grant UL1RR024982 , NIDDK grant T32DK007257 (L. Gregg), and the Center for Depression Research and Clinical Care (Hersh Foundation). The funding organizations had no role in the study design; collection, analysis, and interpretation of the data; writing the report; or the decision to submit the report for publication.

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85079127084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079127084&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2019.09.007

DO - 10.1053/j.ajkd.2019.09.007

M3 - Letter

C2 - 31866226

AN - SCOPUS:85079127084

SN - 0272-6386

VL - 75

SP - 457

EP - 460

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 3

ER -